Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1991 1
1994 1
1995 3
1996 1
1997 1
1998 3
1999 5
2000 5
2001 10
2002 14
2003 13
2004 18
2005 22
2006 11
2007 15
2008 19
2009 16
2010 14
2011 16
2012 18
2013 19
2014 17
2015 25
2016 17
2017 14
2018 13
2019 20
2020 26
2021 12
2022 9
2023 13
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

369 results

Results by year

Filters applied: . Clear all
Page 1
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. Molina JM, et al. Among authors: peytavin g. N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1. N Engl J Med. 2015. PMID: 26624850 Free article. Clinical Trial.
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group. Ader F, et al. Among authors: peytavin g. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14. Lancet Infect Dis. 2022. PMID: 34534511 Free PMC article. Clinical Trial.
Extensive levamisole-induced vasculitis.
Desvignes C, Becquart C, Launay D, Terriou L, Patenotre P, Deheul S, Peytavin G, Dupin N, Delaporte E, Staumont-Sallé D. Desvignes C, et al. Among authors: peytavin g. Clin Exp Dermatol. 2017 Jun;42(4):413-415. doi: 10.1111/ced.13085. Epub 2017 Apr 10. Clin Exp Dermatol. 2017. PMID: 28397288
Reply.
Boyd A, Peytavin G, Lacombe K. Boyd A, et al. Among authors: peytavin g. Hepatology. 2016 Sep;64(3):1000-1. doi: 10.1002/hep.28463. Epub 2016 Mar 7. Hepatology. 2016. PMID: 26784682 No abstract available.
Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study.
Mandelbrot L, Tubiana R, Frange P, Peytavin G, Le Chenadec J, Canestri A, Morlat P, Brunet-Cartier C, Sibiude J, Peretti D, Chambrin V, Chabrol A, Bui E, Simon-Toulza C, Marchand L, Paul C, Delmas S, Avettand-Fenoel V, Warszawski J; Monogest study group. Mandelbrot L, et al. Among authors: peytavin g. J Antimicrob Chemother. 2023 Jul 5;78(7):1711-1722. doi: 10.1093/jac/dkad161. J Antimicrob Chemother. 2023. PMID: 37248782 Free PMC article. Clinical Trial.
Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
Benaboud S, Solas C, Bouchet S, Gregoire M, Lemaitre F, Venisse N, Lê MP, Muret P, Parant F, Neant N, Boujafaar S, Lagoutte-Renosi J, Garraffo R, Peytavin G. Benaboud S, et al. Among authors: peytavin g. J Antimicrob Chemother. 2023 Mar 2;78(3):853-854. doi: 10.1093/jac/dkad009. J Antimicrob Chemother. 2023. PMID: 36683308 No abstract available.
Human Immunodeficiency Virus Seroconversion Among Men Who Have Sex With Men Who Use Event-Driven or Daily Oral Pre-Exposure Prophylaxis (CohMSM-PrEP): A Multi-Country Demonstration Study From West Africa.
Laurent C, Yaya I, Cuer B, Sagaon-Teyssier L, Mensah E, Dah TTE, Coulibaly A, Kouamé MJ, Peytavin G, Serrano L, Eubanks A, Traoré I, Diallo F, Riegel L, Rojas Castro D, Dagnra CA, Anoma C, Vuylsteke B, Dembélé Keita B, Spire B; CohMSM-PrEP Study Group. Laurent C, et al. Among authors: peytavin g. Clin Infect Dis. 2023 Aug 22;77(4):606-614. doi: 10.1093/cid/ciad221. Clin Infect Dis. 2023. PMID: 37052469
369 results